デフォルト表紙
市場調査レポート
商品コード
1480837

生物製剤の世界市場

Biologics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 293 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
生物製剤の世界市場
出版日: 2024年05月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 293 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

生物製剤の世界市場は2030年までに6,568億米ドルに達する見込み

2023年に3,776億米ドルと推定された生物製剤の世界市場は、2030年には6,568億米ドルに達し、分析期間2023-2030年のCAGRは8.2%で成長すると予測されます。本レポートで分析したセグメントの1つである組換え治療用タンパク質は、CAGR 8.8%を記録し、分析期間終了までに2,466億米ドルに達すると予想されます。血液・血液成分セグメントの今後7年間のCAGR成長率は7.5%と推定されます。

米国市場は推定1,162億米ドル、中国はCAGR 7.6%で成長予測

米国の生物製剤市場は、2023年には1,162億米ドルになると推定されます。世界第2位の経済大国である中国は、2023年から2030年までの分析期間においてCAGR 7.6%で推移し、2030年には市場規模が1,119億米ドルに達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、それぞれ2023年から2030年にかけて7.7%と6.6%の成長が予測されています。欧州では、ドイツがCAGR約6.5%で成長すると予測されています。

2024年の魅力的な新レポート機能のご紹介

インフルエンサーのエンゲージメント統計へのフルアクセス

デジタルアーカイブと「MarketGlass」調査プラットフォームへの無料アクセス。当社独自のMarketGlassプラットフォームは、世界中の専門家の創造性と市場知識を統合的かつ協調的に解き放つことができます。当社の最先端のツールは、市場参入企業のプライバシーとアイデンティティを保護しながら、世界クラスの市場展望をもたらします。レポート内の数字、統計、市場に関する説明は、この分野の専門家や影響力のある人々によって共有された、完全にキュレートされた洞察に基づいています。

リアルタイムのデータシミュレーター・ツールや特注のレポート作成機能を備えたインタラクティブなアンケートに参加できます。

企業間のスマートな意見交換のためのピアコラボレーティブ・インタラクティブプラットフォームへのフルクライアントアクセス

1年間の無料レポート更新

主要プレーヤーの世界市場シェアを含む競合カバレッジ

複数の地域にまたがるプレーヤーの市場プレゼンス分析(好調/活発/ニッチ/マイナー)

専門家/インフルエンサーのインタビュー、ポッドキャスト、プレス発表、イベント基調講演のYouTubeビデオへのアクセス

2024年の世界経済に期待すること

金融引き締めとそれに伴う金利上昇によって引き起こされる地政学的、経済的不安定性が、2024年の激動の情勢を作り出すと思われます。中東での敵対行為や、ますます頻発する気候災害など、いくつかの要因が回復への道筋に圧力をかけ続けると思われます。リスクの一方で、ディスインフレの兆候が強まり、頑迷なインフレに対する不安が緩和され、サプライチェーンが正常化し、エネルギーコストの変動にもかかわらず物価が緩やかになるなど、いくつかのプラス材料も具体化しつつあります。インドや米国をはじめとするG21諸国の選挙は、資本の流れや投資戦略に影響を与える可能性があります。インドが世界な投資先として注目される一方で、米国を拠点とするハイテク企業は、才能と資本のダイナミックなエコシステムに後押しされ、引き続き優位を保つと思われます。シリコンバレーをはじめとするハイテク機会は、国内経済が減速しているとはいえ底堅く、規制環境も整備されていることから、高成長の可能性を求める投資家にとって引き続き魅力的です。欧州は金融引き締め政策と景気後退リスクとの戦いが続くが、英国は見通しが最も厳しく、2024年の景気後退リスクが最も高いです。中国は、政府支出と個人消費の改善に支えられた成長が期待されるもの、引き続きワイルドカードとなります。不安定な環境は、投資家にも企業にもチャンスと課題の両方をもたらすと思われます。成長への触媒としてボラティリティを受け入れるとともに、敏捷性と戦略的な先見性をもって投資判断に臨むことが、生き残りのために重要であることに変わりはないです。

調査対象企業の例(全243社)

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP16211

Global Biologics Market to Reach $656.8 Billion by 2030

The global market for Biologics estimated at US$377.6 Billion in the year 2023, is expected to reach US$656.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Recombinant Therapeutic Proteins, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$246.6 Billion by the end of the analysis period. Growth in the Blood & Blood components segment is estimated at 7.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $116.2 Billion, While China is Forecast to Grow at 7.6% CAGR

The Biologics market in the U.S. is estimated at US$116.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$111.9 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 6.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 243 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biologics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Recombinant Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Recombinant Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Recombinant Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Blood & Blood components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Blood & Blood components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Blood & Blood components by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cellular & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cellular & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Cellular & Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 31: World Biologics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Biologics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Biologics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION